Hansa Biopharma AB (publ) (STO:HNSA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 3.94B +12.4% |
| Revenue (ttm) | 189.46M -3.6% |
| Net Income | -755.14M |
| EPS | -7.74 |
| Shares Out | 101.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 646,531 |
| Open | 39.38 |
| Previous Close | 39.34 |
| Day's Range | 38.10 - 40.00 |
| 52-Week Range | 23.52 - 48.22 |
| Beta | 1.68 |
| Analysts | Strong Buy |
| Price Target | 73.00 (+88.44%) |
| Earnings Date | Nov 11, 2026 |
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune... [Read more]
Financial Performance
In 2025, Hansa Biopharma AB's revenue was 222.27 million, an increase of 29.74% compared to the previous year's 171.32 million. Losses were -534.11 million, -33.84% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for HNSA stock is "Strong Buy." The 12-month stock price target is kr 73.00, which is an increase of 88.44% from the latest price.
News
Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week
The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix was generally well tole...
Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
Hansa is deploying Cradle's end-to-end platform to develop novel immunomodulatory therapies in autoimmune disease. AMSTERDAM, Oct. 1, 2026 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA),...
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney tran...
Hansa Biopharma AB Slides: Corporate presentation
Hansa Biopharma AB has posted slides in relation to its latest quarterly earnings report, which was published on July 24, 2026.
Hansa Biopharma AB Earnings Call Transcript: Q2 2026
Q2 2026 saw a transformative out-licensing deal for IDEFIRIX in Europe, strong clinical data, and robust U.S. launch preparations. Revenue was SEK 48.1 million, with a strengthened cash position post-SERB deal, and positive outlook for both European and U.S. markets.
Hansa Biopharma AB Quarterly report: Q2 2026
Hansa Biopharma AB has published its Q2 2026 quarterly earnings report on July 22, 2026.
Hansa Biopharma AB Slides: Q2 2026
Hansa Biopharma AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 22, 2026.
Hansa Biopharma AB Slides: Corporate presentation
Hansa Biopharma AB has posted slides in relation to its latest quarterly earnings report, which was published on July 2, 2026.
Hansa Biopharma participating in Wedbush PacGrow Renal Summit
LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fire...
Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly strengthen...
Hansa Biopharma AB Transcript: CMD 2026
Imlifidase demonstrated strong efficacy and safety in both clinical trials and real-world use, enabling transplants for highly sensitized patients previously considered untransplantable. U.S. launch preparations are advanced, with regulatory approval expected by year-end and early adoption anticipated in experienced centers.
Hansa Biopharma AB Slides: FY 2026
Hansa Biopharma AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 25, 2026.
Hansa Biopharma initiated with a Buy at Danske Bank
Danske Bank initiated coverage of Hansa Biopharma (HNSBF) with a Buy rating and SEK 53 price target The firm sees a positive U.S. launch of imlifidase in 2027. Published first…
Hansa Biopharma AB Transcript: Jefferies Global Healthcare Conference 2026
A novel IgG degrader platform targets highly sensitized kidney transplant patients, with imlifidase showing strong phase III results and a $1B+ U.S. market opportunity. U.S. launch preparations are advanced, with regulatory and commercial milestones set for 2024, and a robust cash position supports growth.
Hansa Biopharma AB Transcript: Study result
The PAES study showed that imlifidase enables highly sensitized kidney transplant patients to achieve one-year graft failure-free survival of 89.6%, with patient survival at 97.9% and a favorable safety profile. Results were consistent with prior data and support full EMA approval.
Hansa Biopharma AB Press release: Study result
Hansa Biopharma AB issued a press release on May 27, 2026, disclosing material business information to investors.
Hansa Biopharma AB Slides: Study result
Hansa Biopharma AB has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission Idefirix was generally well tolerated with a safety profile consiste...
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
LUND, Sweden, May 26, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been acc...
Hansa Biopharma AB Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Imlifidase enables rapid desensitization for highly sensitized kidney transplant patients, showing strong clinical results and addressing a significant unmet need. The company monetized European rights for up to EUR 150 million to fund a robust U.S. launch and pipeline expansion, including next-gen therapies for autoimmune diseases.
Hansa Biopharma AB Transcript: Investor update
IDEFIRIX was out-licensed for €110 million upfront plus a €5 million milestone, enabling broader European reach and significant non-dilutive funding. The deal extends cash runway, supports a robust U.S. launch, and reduces European costs, with key data and regulatory milestones ahead.
Hansa Biopharma AB Press release: Investor update
Hansa Biopharma AB issued a press release on May 19, 2026, disclosing material business information to investors.
Hansa Biopharma AB Slides: Investor update
Hansa Biopharma AB has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region Significantly enhances Hansa's financial position, ensuring a robust U.S. launc...
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
SERB Pharmaceuticals to acquire development and commercialisation rights to Idefirix® (imlifidase) in Europe and MENA from Hansa Biopharma for €115 million